Acorda Therapeutics (NASDAQ:ACOR) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Acorda Therapeutics (NASDAQ:ACOR) in a research report report published on Wednesday. The firm issued a buy rating on the biopharmaceutical company’s stock.

Acorda Therapeutics Stock Performance

Shares of ACOR stock opened at $11.91 on Wednesday. The stock has a market cap of $14.77 million, a P/E ratio of -0.70 and a beta of 1.41. The company has a debt-to-equity ratio of 3.07, a current ratio of 1.59 and a quick ratio of 1.21. The company has a fifty day moving average price of $14.38 and a two-hundred day moving average price of $13.15. Acorda Therapeutics has a one year low of $8.98 and a one year high of $24.20.

Institutional Trading of Acorda Therapeutics

Hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its stake in shares of Acorda Therapeutics by 1.5% during the 4th quarter. Renaissance Technologies LLC now owns 868,892 shares of the biopharmaceutical company’s stock worth $666,000 after buying an additional 13,100 shares during the last quarter. Vanguard Group Inc. bought a new stake in shares of Acorda Therapeutics during the 3rd quarter valued at approximately $161,000. Millennium Management LLC grew its holdings in shares of Acorda Therapeutics by 661.2% during the 2nd quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 270,588 shares during the last quarter. Susquehanna International Group LLP grew its holdings in shares of Acorda Therapeutics by 1,759.1% during the 1st quarter. Susquehanna International Group LLP now owns 218,830 shares of the biopharmaceutical company’s stock valued at $128,000 after purchasing an additional 207,059 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in shares of Acorda Therapeutics during the 2nd quarter valued at approximately $68,000. Institutional investors and hedge funds own 12.71% of the company’s stock.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen.